{"schema_version":"secwatch.filing_event.v1","accession":"0001778922-26-000004","form_type":"8-K","ticker":"SGP","cik":"0001778922","company_name":"SpyGlass Pharma, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.147077+00:00","generated_at":"2026-05-15T18:04:03.998575+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops","bullets":["97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.","Mean IOP reduction from baseline: 34% (78-mcg) and 42% (39-mcg) vs 35% for timolol control.","100% of BIM-IOL patients achieved BCDVA of 20/32 or better; mean BCDVA equivalent to 20/20.","Adverse event rates similar across groups (36.7%-43.5%); no serious ocular AEs observed.","Company is enrolling two identical registrational Phase 3 trials of the 78-mcg dose (initiated Jan 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001778922-26-000004","json":"https://secwatch.observer/filing/0001778922-26-000004.json","markdown":"https://secwatch.observer/filing/0001778922-26-000004.md","text":"https://secwatch.observer/filing/0001778922-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/0001778922-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/sgp-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:04:03.998575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}